diurizone injectable
vetoquinol ireland limited - hydrochlorothiazide; dexamethasone - solution for injection - 50, 0.5 milligram(s)/millilitre - hydrochlorothiazide, combinations - cattle, non food-producing horses - cardiovascular
diurizone powder
vetoquinol ireland limited - dexamethasone; hydrochlorothiazide - oral powder - 0.25, 75.0 milligram(s)/gram - hydrochlorothiazide, combinations - cattle, non food-producing horses - cardiovascular
diurizone solução injetável para bovinos e equinos
vétoquinol - dihidroclorotiazida 5.0 g ; dexametasona 0.05 g - solução injetável - associações de hidroclorotiazida - bovinos, equinos (não destinados ao consumo humano)
diurizone injectable
vetoquinol ireland limited - hydrochlorothiazide, dexamethasone - solution for injection - unknown - hydrochlorothiazide, combinations - bovine, equine non food - cardiovascular
diurizone poudre
vetoquinol - dexaméthasone, hydrochlorothiazide - poudre pour suspension buvable - diurétique associé à un anti-inflammatoire - bovins
diurizone solution
vetoquinol - dexaméthasone, hydrochlorothiazide - solution injectable - diurétique associé à un anti-inflammatoire - bovins
diurizone powder
vetoquinol ireland limited - dexamethasone, hydrochlorothiazide - oral powder - 0.025/7.5 - hydrochlorothiazide, combinations - bovine, equine non food - cardiovascular
milrinone carinopharm 1 mg/ml, solution injectable/pour perfusion
carinopharm gmbh - milrinone 1 mg - solution - 1 mg - pour 1 ml de solution > milrinone 1 mg - inhibiteur sélectif de la phosphodiestérase - milrinone carinopharm est un médicament qui sert à augmenter le débit cardiaque (performance du cœur). il contient une substance active appelée milrinone. il s’agit d’une substance dont les propriétés augmentent la force de contraction du cœur et dilatent les vaisseaux sanguins.milrinone carinopharm peut être utilisé chez les adultes pour : le traitement de courte durée de l’insuffisance cardiaque congestive sévère (quand le cœur a des difficultés pour pomper le sang du corps) si d’autres médicaments n’ont pas été efficaces.milrinone carinopharm peut être utilisé chez les enfants pour : le traitement de courte durée (jusqu’à 35 heures) de l’insuffisance cardiaque congestive sévère (quand le cœur a des difficultés pour pomper le sang du corps) si d’autres médicaments n’ont pas été efficaces ; le traitement de courte durée (jusqu’à 35 heures) de l’insuffisance cardiaque aiguë après une opération du cœur, c’est-à-dire quand le cœur a des difficultés pour pomper le sang du corps.l’utilisation de milrinone carinopharm doit s’effectuer sous contrôle constant de la fonction cardiaque et de la pression artérielle.
milrinone lactate injection, solution
hikma pharmaceuticals usa inc. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone lactate 10 mg in 10 ml - milrinone lactate injection, usp and milrinone lactate in 5% dextrose injection are indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate injection, usp and milrinone lactate in 5% dextrose injection are contraindicated in patients who are hypersensitive to it.
milrinone lactate injection
west-ward pharmaceutical corp. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone 1 mg in 1 ml - milrinone lactate injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate injection is contraindicated in patients who are hypersensitive to it.